Indo Us Bio-Tech Ltd
Indo Us Bio-Tech Ltd (INDOUS) last reported results for the quarter ended Jun 2026, with sales of ₹32.99 crore and net profit of ₹3.04 crore. The stock last traded at ₹71.7, a market capitalisation of ₹144 crore, on a P/E of 12.6. Over the past 52 weeks the stock has ranged between ₹70 and ₹159. Figures are as of 6 Oct 2026 and are not real time.
Indo Us Bio-Tech Ltd share price and key metrics
- Current price
- ₹71.7
- Market cap
- ₹144 cr
- Stock P/E
- 12.6
- Book value
- ₹46.2
- ROE
- 15.3%
- ROCE
- 14.5%
- Dividend yield
- 0.00%
- 52w high / low
- 159/70.0
Metrics as of 6 Oct 2026. Not real time.
Track Indo Us Bio-Tech Ltd
Cruxal reads every Indo Us Bio-Tech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Indo Us Bio-Tech Ltd growth and returns
- 10 Years
- 19%
- 5 Years
- 23%
- 3 Years
- 22%
- TTM
- 3%
- 10 Years
- 43%
- 5 Years
- 21%
- 3 Years
- 22%
- TTM
- -36%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- -32%
- 1 Year
- -42%
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 18%
- Last Year
- 15%
Indo Us Bio-Tech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹32.99 cr, up 7.2% from ₹30.77 cr a year earlier. Net profit was ₹3.04 cr, down 35.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 22.17 | 23.56 | 33.38 | 30.77 | 30.85 | 22.8 | 26.02 | 32.99 |
| Expenses | 17.05 | 18.02 | 28.8 | 25.3 | 26.69 | 18.65 | 22.79 | 29.02 |
| Operating profit | 5.12 | 5.54 | 4.58 | 5.47 | 4.16 | 4.15 | 3.23 | 3.97 |
| OPM % | 23.09% | 23.51% | 13.72% | 17.78% | 13.48% | 18.20% | 12.41% | 12.03% |
| Other income | 0.02 | 0.02 | 0.12 | 0 | 0.03 | 0.01 | 0.02 | 0.12 |
| Interest | 0.52 | 0.38 | 0.26 | 0.45 | 0.42 | 0.77 | 0.6 | 0.74 |
| Depreciation | 0.18 | 0.16 | 0.56 | 0.2 | 0.21 | 0.22 | 0.27 | 0.27 |
| Profit before tax | 4.44 | 5.02 | 3.88 | 4.82 | 3.56 | 3.17 | 2.38 | 3.08 |
| Tax % | 2.03% | -0.80% | 4.90% | 2.49% | 3.09% | 5.36% | 17.23% | 1.30% |
| Net profit | 4.36 | 5.05 | 3.68 | 4.7 | 3.45 | 3 | 1.97 | 3.04 |
| EPS (₹) | 2.17 | 2.52 | 1.84 | 2.34 | 1.72 | 1.50 | 0.98 | 1.52 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indo Us Bio-Tech Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 29 | 35 | 40 | 39 | 49 | 61 | 73 | 104 | 110 | 113 |
| Operating profit | 1 | 3 | 3 | 4 | 6 | 7 | 9 | 11 | 19 | 17 | 16 |
| OPM % | 5% | 9% | 10% | 10% | 14% | 14% | 15% | 15% | 18% | 15% | 14% |
| Net profit | 0 | 1 | 2 | 3 | 5 | 5 | 7 | 8 | 16 | 13 | 11 |
| EPS (₹) | 0.89 | 1.41 | 1.44 | 1.74 | 3.52 | 2.86 | 3.60 | 4.11 | 8.11 | 6.54 | 5.72 |
TTM is the trailing twelve months to the most recent quarter.
Indo Us Bio-Tech Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 3 | 5 | 6 | 6 | 9 | 10 | 20 | 20 | 20 |
| Reserves | 2 | 2 | 9 | 10 | 15 | 30 | 44 | 43 | 58 | 72 |
| Borrowings | 5 | 7 | 6 | 9 | 11 | 12 | 12 | 14 | 15 | 37 |
| Other liabilities | 4 | 6 | 4 | 10 | 11 | 4 | 3 | 7 | 4 | 4 |
| Total liabilities | 13 | 17 | 24 | 35 | 44 | 56 | 69 | 84 | 98 | 133 |
| Fixed assets | 1 | 2 | 1 | 1 | 2 | 6 | 7 | 7 | 10 | 11 |
| CWIP | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 11 | 16 | 21 | 32 | 39 | 48 | 61 | 74 | 88 | 121 |
| Total assets | 13 | 17 | 24 | 35 | 44 | 56 | 69 | 84 | 98 | 133 |
As reported by the company. Total assets equal total liabilities by construction.
Indo Us Bio-Tech Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | -1 | -3 | -1 | 0 | 3 | 1 | 2 | 1 | -13 |
| Cash from investing | -0 | 0 | -3 | -1 | -2 | -5 | -7 | -3 | -1 | -2 |
| Cash from financing | 0 | 1 | 6 | 2 | 1 | 2 | 6 | 1 | -1 | 20 |
| Net cash flow | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 1 | -1 | 6 |
| Free cash flow | -0 | -1 | -4 | -1 | -2 | -1 | -1 | -0 | 1 | -15 |
| CFO / operating profit | 11% | -16% | -92% | -20% | 6% | 47% | 9% | 23% | 9% | -71% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Indo Us Bio-Tech Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 14% | 28% | 20% | 17% | 18% | 16% | 15% | 14% | 21% | 14% |
| Debtor days | 76 | 112 | 94 | 193 | 229 | 152 | 148 | 95 | 53 | 45 |
| Inventory days | 92 | 98 | 176 | 751 | — | — | — | — | — | — |
| Days payable | 64 | 71 | 34 | 667 | — | — | — | — | — | — |
| Cash conversion cycle | 104 | 138 | 236 | 276 | 229 | 152 | 148 | 95 | 53 | 45 |
| Working capital days | 34 | 59 | 129 | 137 | 186 | 257 | 285 | 266 | 247 | 248 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Indo Us Bio-Tech Ltd shareholding pattern
Promoters held 68.29% at Jun 2026, down from 70.18% at Jun 2025. FIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.18% | 70.18% | 70.18% | 70.18% | 70.18% | 70.18% | 68.29% | 68.29% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | 0.01% |
| Public | 29.83% | 29.82% | 29.83% | 29.83% | 29.83% | 29.83% | 31.53% | 31.70% |
| No. of shareholders | 971 | 2,828 | 2,780 | 3,112 | 4,130 | 4,738 | 4,531 | 4,690 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Indo Us Bio-Tech Ltd corporate filings
- Indo Us Bio Tech Limited's Voting Results Confirm Strong Shareholder Support for Key Resolutions at 22nd AGMAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio Tech Limited reported near-unanimous shareholder approval for all resolutions…
Read the full analysis - Indo Us Bio-Tech Limited Conducts 22nd AGM; No Financial Impact Data DisclosedAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio-Tech Limited held its 22nd Annual General Meeting on September 30, 2026, via…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Indo Us Bio-Tech Limited Announces 22nd Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting (AGM) to…
Read the full analysis - Indo Us Bio-Tech Ltd releases Annual Report for the financial year 2025-26Otherslow impact
Cruxal's analysis: Indo Us Bio-Tech Ltd has filed its Annual Report for the fiscal year 2025-26 as per…
Read the full analysis - Indo US Bio-Tech Limited announces 22nd AGM, seeks shareholder approval for enhanced borrowing limits and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Indo US Bio-Tech Limited has scheduled its 22nd Annual General Meeting for September 30…
Read the full analysis - Indo Us Bio-Tech Limited Announces 22nd Annual General Meeting and Seeks Shareholder Approval for Borrowing Limits up to 250 Crore INRAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting…
Read the full analysis - Indo US Bio-Tech Limited Announces 22nd Annual General Meeting and Statutory Auditor AppointmentOtherslow impact
Cruxal's analysis: Indo US Bio-Tech Limited has scheduled its 22nd Annual General Meeting for September 30…
Read the full analysis - Indo Us Bio-Tech Limited reports Q1 FY2027 standalone net profit of 3.04 croreCompany Updatemedium impact
Cruxal's analysis: Indo Us Bio-Tech Limited has released its unaudited standalone financial results for the…
Read the full analysis - Indo US Bio-Tech Limited Reports Strong Q1 FY27 Financials with 7.2% YoY Revenue Growth and 303.74 Lakh Net ProfitResultmedium impact
Cruxal's analysis: Indo US Bio-Tech Limited reported standalone unaudited financial results for the quarter…
Read the full analysis - Indo US Bio-Tech Limited Reports Q1 FY27 Financial Results with Revenue Growth of 7.2% YoYBoard Meetingmedium impact
Cruxal's analysis: Indo US Bio-Tech Limited reported standalone revenue from operations of 32.99 crore for…
Read the full analysis - Indo Us Bio Tech Limited Announces Results of Postal Ballot for Director Appointment and Statutory Auditor ChangeAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio Tech Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Indo Us Bio Tech Limited Announces Results of Postal Ballot for Director Appointment and Statutory AuditorAGM/EGMlow impact
Cruxal's analysis: Indo Us Bio Tech Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Indo Us Bio Tech to Hold Board Meeting on August 12, 2026, to Approve Q1 FY27 Financial ResultsBoard Meetinglow impact
Cruxal's analysis: Indo Us Bio Tech Limited has announced that its Board of Directors will convene a meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.